NRx Pharmaceuticals Inc (NRXPW) - Total Assets
Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) holds total assets worth $11.90 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NRXPW equity financing ratio to measure how much of total assets are equity-financed.
NRx Pharmaceuticals Inc - Total Assets Trend (2017–2025)
This chart illustrates how NRx Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore NRx Pharmaceuticals Inc (NRXPW) long-term investment share to see how much of total assets are deployed in long-term investments.
NRx Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
NRx Pharmaceuticals Inc's total assets of $11.90 Million consist of 68.6% current assets and 31.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.2% |
| Accounts Receivable | $161.00K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $925.00K | 7.1% |
| Goodwill | $1.79 Million | 13.8% |
Asset Composition Trend (2017–2025)
This chart illustrates how NRx Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NRx Pharmaceuticals Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NRx Pharmaceuticals Inc's current assets represent 68.6% of total assets in 2025, an increase from 0.8% in 2017.
- Cash Position: Cash and equivalents constituted 60.2% of total assets in 2025, up from 0.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 13.8% of total assets.
NRx Pharmaceuticals Inc Competitors by Total Assets
Key competitors of NRx Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
NRx Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.22 | 0.52 |
| Quick Ratio | 0.29 | 0.22 | 0.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-17.82 Million | $-25.50 Million | $-16.94 Million |
NRx Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between NRx Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 254.9% |
| Total Assets | $12.96 Million |
| Market Capitalization | $141.94 USD |
Valuation Analysis
Below Book Valuation: The market values NRx Pharmaceuticals Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NRx Pharmaceuticals Inc's assets grew by 254.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual total assets of NRx Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.96 Million | +254.86% |
| 2024-12-31 | $3.65 Million | -50.09% |
| 2023-12-31 | $7.32 Million | -71.66% |
| 2022-12-31 | $25.82 Million | -21.12% |
| 2021-12-31 | $32.73 Million | +1012.85% |
| 2020-12-31 | $2.94 Million | -90.83% |
| 2019-12-31 | $32.07 Million | -54.69% |
| 2018-12-31 | $70.80 Million | +1.77% |
| 2017-12-31 | $69.57 Million | -- |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more